Comparative Pharmacology
Head-to-head clinical analysis: HYDASE versus XIAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDASE versus XIAFLEX.
HYDASE vs XIAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYDASE (hyaluronidase) hydrolyzes hyaluronic acid, a glycosaminoglycan in the extracellular matrix, thereby increasing tissue permeability and facilitating the dispersion and absorption of injected fluids or drugs.
XIAFLEX (collagenase clostridium histolyticum) is a combination of two collagenases (AUX-I and AUX-II) that hydrolyze collagen in the extracellular matrix. It targets type I and type III collagen, leading to enzymatic disruption of collagen-rich structures such as Dupuytren's cords and Peyronie's plaques.
Intravenous, intramuscular, or subcutaneous: 150-300 units (0.5-1 mL) as a single dose or divided into multiple doses to facilitate hydration and dispersion of other injected drugs. Frequency: as needed based on clinical indication, up to every 2-3 days.
0.58 mg injected directly into the palpable cord, up to 3 injections per treatment session (one per affected cord) at intervals of 1–2 days apart; repeated every 4 weeks as needed, up to 3 treatment sessions per cord.
None Documented
None Documented
2 to 5 minutes intravenously; rapidly inactivated by proteases in plasma and tissues, resulting in ultra-short duration.
Systemic half-life not applicable due to minimal systemic absorption. Locally, collagenase activity declines within 1-2 days post-injection.
Primarily renal; <1% excreted unchanged in urine; extensive metabolism via proteolysis to amino acids and peptides.
Primarily metabolized locally; systemic absorption minimal. No renal or biliary excretion data available; eliminated via local degradation.
Category C
Category C
Enzyme
Enzyme